Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

Todd Neale

October 28, 2024

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

L.A. McKeown

October 28, 2024

Presentation TCT 2024

TCT 887: SAPIEN 3 Ultra Resilia: Bench Insights to Hydrodynamic Function for TAVR, Valve-in-Valve and Redo-TAVR

Presenter: Julien Delarive

October 28, 2024

Presentation TCT 2024

TCT 160: Edwards Sapien 3 Ultra Resilia Valves Demonstrate Lower Gradients at 1 Year Compared to Sapien 3 Ultra Valves

Presenter: Joseph Aragon

October 28, 2024

Presentation TCT 2024

TCT 164: Immediate and Pre-Discharge Post-TAVR Invasive and Echocardiographic Hemodynamics of Sapien 3 Resilia, Sapien 3 Ultra and Self-Expanding Valves

Presenter: Shazil Mahmood

October 28, 2024

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

Presentation TCT 2024

TCT 86: Real-World 30-Day Outcomes for the SAPIEN 3 Ultra Resilia Transcatheter Heart Valve in the Treatment of Failed Bioprosthetic Mitral Valves: A Propensity-Matched Analysis

Presenter: Tiberio Frisoli

October 27, 2024

Advertisement

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

TCT 887: SAPIEN 3 Ultra Resilia: Bench Insights to Hydrodynamic Function for TAVR, Valve-in-Valve and Redo-TAVR

TCT 160: Edwards Sapien 3 Ultra Resilia Valves Demonstrate Lower Gradients at 1 Year Compared to Sapien 3 Ultra Valves

TCT 164: Immediate and Pre-Discharge Post-TAVR Invasive and Echocardiographic Hemodynamics of Sapien 3 Resilia, Sapien 3 Ultra and Self-Expanding Valves

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

TCT 86: Real-World 30-Day Outcomes for the SAPIEN 3 Ultra Resilia Transcatheter Heart Valve in the Treatment of Failed Bioprosthetic Mitral Valves: A Propensity-Matched Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content